Application 216143
- Type
- ANDA
- Sponsor
- RHODES PHARMS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | MARAVIROC | MARAVIROC | TABLET;ORAL | 150MG | No | No |
| 002 | MARAVIROC | MARAVIROC | TABLET;ORAL | 300MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A216143-001 | MARAVIROC | MARAVIROC | 150MG | TABLET / ORAL | 2025-11-04 | ||
| A216143-002 | MARAVIROC | MARAVIROC | 300MG | TABLET / ORAL | 2025-11-04 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A216143-001 | MARAVIROC | 150MG | TABLET / ORAL | AB | 2025-11-04 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A216143-002 | MARAVIROC | 300MG | TABLET / ORAL | AB | 2025-11-04 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A216143-001 | MARAVIROC | 150MG | TABLET / ORAL | AB | 2025-11-04 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A216143-002 | MARAVIROC | 300MG | TABLET / ORAL | AB | 2025-11-04 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A216143-001 | MARAVIROC | 150MG | TABLET / ORAL | 2025-11-04 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A216143-002 | MARAVIROC | 300MG | TABLET / ORAL | 2025-11-04 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A216143-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A216143-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A216143-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A216143-002 | AB | 1 | 31067a03dcf5… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Maraviroc | MARAVIROC | A-S Medication Solutions | 5c4a1da5-a8e1-4038-970d-fb15c189c35e | 2026-07-08 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | A-S Medication Solutions | 0c5f41e8-d358-403a-b199-6b9028b52748 | 2026-06-26 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | Navinta LLC | 211290a4-5e26-4784-aa99-8ccaf2eaaa15 | 2025-06-23 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | Zydus Pharmaceuticals USA Inc. | 9bba17ba-0bc5-430c-96d1-c568e236a0ed | 2025-05-15 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | A2A Integrated Pharmaceuticals | 2a16417d-a3b8-483b-9dfe-d5263cc16538 | 2025-02-28 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | Hetero Labs Limited | 9db91945-127e-4bb6-970a-ff1e36dde658 | 2024-07-04 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| SELZENTRY | MARAVIROC | A-S Medication Solutions | 3c52dddd-0457-41cd-99e0-d30d4fd00ec5 | 2023-11-10 | Boxed warning, Warnings, Adverse reactions | MARAVIROC |
| Maraviroc | MARAVIROC | i3 Pharmaceuticals, LLC | f7b9c67b-10c6-45b5-b2a8-952cd350b0b1 | 2023-08-18 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| Maraviroc | MARAVIROC | XLCare Pharmaceuticals Inc. | d3a728e2-1866-462e-bfcc-5f3c9dd88794 | 2023-07-12 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |
| SELZENTRY | MARAVIROC | ViiV Healthcare Company | 46f30ac5-c96b-429e-976d-8c5ee1c0761b | 2022-09-26 | Boxed warning, Warnings, Adverse reactions | MARAVIROC |
| Maraviroc | MARAVIROC | Camber Pharmaceuticals, Inc. | 09ec3e79-c0d3-4b8f-80d8-0a854c4ca339 | 2022-01-27 | Boxed warning, Warnings, Adverse reactions | Maraviroc MARAVIROC |